https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-03-07 / Tumour Biol. 2016 Aug;37(8):11267-78
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-03-07 / Tumour Biol. 2016 Aug;37(8):11267-782016-03-07 00:00:002019-02-15 08:47:52Antigen-specific T cell response from dendritic cell vaccination using side population cell-associated antigens targets hepatocellular carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-03-04 / Cancer Sci. 2016 Apr;107(4):514-20
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-03-04 / Cancer Sci. 2016 Apr;107(4):514-202016-03-04 00:00:002016-03-04 00:00:00Cetuximab delivery and antitumor effects are enhanced by mild hyperthermia in a xenograft mouse model of pancreatic cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-03-02 / Sci Transl Med 2016 Mar;8(328):328ra27
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-03-02 / Sci Transl Med 2016 Mar;8(328):328ra272016-03-02 00:00:002022-09-29 14:06:28Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade glioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-03-01 / Oman Med J 2016 Mar;31(2):89-97
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-03-01 / Oman Med J 2016 Mar;31(2):89-972016-03-01 00:00:002019-02-15 09:18:11Hyperthermia: How Can It Be Used?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-03-01 / J. Acquir. Immune Defic. Syndr. 2016 Mar;71(3):246-53
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-03-01 / J. Acquir. Immune Defic. Syndr. 2016 Mar;71(3):246-532016-03-01 00:00:002019-02-15 08:48:03Immunization of HIV-1-Infected Persons With Autologous Dendritic Cells Transfected With mRNA Encoding HIV-1 Gag and Nef: Results of a Randomized, Placebo-Controlled Clinical Trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-02-24 / Oncol Lett 2016 Apr;11(4):2605-2610
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-02-24 / Oncol Lett 2016 Apr;11(4):2605-26102016-02-24 00:00:002019-02-15 08:45:42Dendritic cell vaccine and cytokine-induced killer cell therapy for the treatment of advanced non-small cell lung cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-02-10 / Cancer Immunol. Immunother. 2016 Mar;65(3):327-39
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-02-10 / Cancer Immunol. Immunother. 2016 Mar;65(3):327-392016-02-10 00:00:002019-02-15 08:49:42Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-02-09 / Ther Adv Urol 2016 Jun;8(3):203-14
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-02-09 / Ther Adv Urol 2016 Jun;8(3):203-142016-02-09 00:00:002016-02-09 00:00:00Novel immunotherapeutic approaches to the treatment of urothelial carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-02-01 / Melanoma Res. 2016 Feb;26(1):1-11
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-02-01 / Melanoma Res. 2016 Feb;26(1):1-112016-02-01 00:00:002019-02-15 08:49:37Type I-polarized BRAF-pulsed dendritic cells induce antigen-specific CD8+ T cells that impact BRAF-mutant murine melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-01-22 / J. Exp. Clin. Cancer Res. 2016 Jan;35:18
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-01-22 / J. Exp. Clin. Cancer Res. 2016 Jan;35:182016-01-22 00:00:002019-02-15 08:48:30Eliciting cytotoxic T lymphocytes against human laryngeal cancer-derived antigens: evaluation of dendritic cells pulsed with a heat-treated tumor lysate and other antigen-loading strategies for dendritic-cell-based vaccination
